Healthcare / BiotechnologyNasdaqCM
$1.71
-0.00 (-0.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-7.7M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$90M
P/E
N/A
•EV/EBITDA
N/A
•ROE
84.8%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-4.7M · FCF $-1.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-4.7M | $-4.7M | $-16.8M | $-13.3M | $-5.4M |
| EBITDA | $-7.1M | $-7.1M | $-15.7M | $-13.2M | $-6.2M |
| EPS | -0.12 | -0.12 | -0.57 | -0.61 | -0.36 |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | -1.08 | — |
| Current Ratio | 0.58 | 0.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.8M | $-1.8M | $-9.5M | $-7.7M | $-5.5M |
| Returns | |||||
| ROE | 84.8% | 84.8% | 286.2% | 646.4% | -184.3% |
| Growth & Yield | |||||
| EPS Growth | 79.1% | 79.1% | 6.6% | -69.4% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.57 → -0.12
Residual
-7.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.